To join this class action, please complete the following Investor Certification.
Oklahoma City, OK (August 17, 2021) – Federman & Sherwood is investigating Sesen Bio (NASDAQ: SESN) for potential securities law violations. The allegations are of violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price. More specifically, after the company announced their second quarter 2021 earnings, the shares of Sesen Bio traded up over 50% since the market opened on August 9, 2021. On August 13, 2021, Sesen Bio announced that the U.S. Food and Drug Administration (FDA) declined to approve the Company’s Biologics License Application (BLA) for its bladder cancer treatment Vicineum which resulted in a drastic drop in the stock.
The lawsuit seeks to recover damages on behalf of all Sesen Bio investors who purchased common stock during the Class Period.
If you wish to obtain further information and participate in this or any other securities litigation, or should you have any questions regarding this notice or preservation of your rights, please contact: Priscilla Scoggins at pms@federmanlaw.com